1HUANG SM, BOCK JM, HARARI PM. Epidermal growth factor receptor blockade C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck[J]. Cancer Res, 1999, 59(8) : 1935-1940.
3LANGERAK A, RIVER G, MITCHELL E. Panitumumab monotherapy in patients with metastatic colorectal cancer and cetuximab infusion reactions : a series of four case reports[J]. Clin Colorectal Cancer, 2009, 8 (1) : 49-54.
5Ciardiello F,Tortota G,Anovel G.Approach in the treatment of cancer targeting the epidermal growth factor receptor[J].Clin Cancer Res,2001,7:2958-2970.
6Venook AP.Epidermal growth factor receptor targeted treatment of for Advanced colorectal carcinoma[J].Cancer,2005,103(2):2435-2446.
3SALTZ LB, COX JV, BLANKE C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer[J]. N Engl J Med, 2000, 343(13): 905-914.
4ROSENOF SH, GABRAIL NY, CONKLIN R, etal. A multicenter,randomized trial of long-acting octreotide for the optimum prevention of chemotherapy--induced diarrhea:results of the STOP trial[J]. J Support Oncol, 2006, 4(6) : 289-294.
5GOUMAS P, NAXAKIS S, CHRISTOPOULOU A, etal. Octreo-ide acetate in the treatment of fluorouracil-induced diarrhea[J]. Oncologist, 1998, 3(1): 50-53.
6LIMONTI A, GELIBTER A, PAVESE I , et al. New approaches to prevent intestinal toxicity of irinotecan-based regimens [J]. Cancer Treat Rev, 2004, 30(6) : 555-562.
7IYER L, DAS S, JANISCH L, et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity [J]. Pharmacogenomics J, 2002, 2 ( 1 ) : 43-47.
8BLICK SK, SCOTT LJ. Cetuximab: a review of its use insquamous cell carcinoma of the head and neck and metastaticcolorectal cancer[J]. Drugs, 2007, 67(17) : 2585-2607.
9MENDELSOHN J, BASELGA J. Status of epidermal growthfactor receptor antagonists in the biology and treatment of cancer[J]. J Clin Oncol, 2003, 21(14): 2787-2799.
